**Potential Lantus to Abasaglar switch for adult T2DM patients.**

**Patients on Lantus**

Is patient having >60 units of Lantus a day?

- **No**
  - Is patient stable?
    - **Yes**
      - Is HbA1c greater than 58mmol?
        - **Yes**
          - Switch to Abasaglar dose for dose.
            - Patient should monitor blood glucose as needed.
            - Review the patient in a week and titrate the dose of Abasaglar as necessary to achieve patient’s target blood glucose levels.
        - **No**
          - Does patient have hypoglycaemic episodes?
            - **No**
              - After dose titration, if patient does not reach target blood glucose, please consider an alternative insulin regimen for the patient.
            - **Yes**
              - Consider switch to Abasaglar but reduce dose by 20%.
                - Verify current Lantus dose and reduce by 20% to give Abasaglar dose.
                - Patient should monitor blood glucose as needed.
                - Review the patient in a week and titrate the dose of Abasaglar as necessary to achieve target blood glucose levels.
                - If the patient continues to suffer from hypos, consider an alternative insulin regimen. Advice can be sought from the DSNs.

- **Yes**
  - Does patient have hypoglycaemic episodes?
    - **No**
      - After dose titration, if patient does not reach target blood glucose, please consider an alternative insulin regimen for the patient.
    - **Yes**
      - Consider switch to Abasaglar but reduce dose by 20%.
        - Verify current Lantus dose and reduce by 20% to give Abasaglar dose.
        - Patient should monitor blood glucose as needed.
        - Review the patient in a week and titrate the dose of Abasaglar as necessary to achieve target blood glucose levels.
        - If the patient continues to suffer from hypos, consider an alternative insulin regimen. Advice can be sought from the DSNs.

**Please note:**
- This switch is supported by the DSNs and secondary care consultant.
- These switches should be carried out as part of a face to face full insulin review, ideally by staff trained in diabetes management. It may be apparent after a review that a straight insulin switch is not the best course of action for the patient.
- For example, the patient may currently be on Lantus however not achieving their target blood glucose levels. Rather than a switch to Abasaglar, biphasic human insulin such as Insuman Comb 25 twice a day maybe more appropriate.
- Please see the CCG guidance on insulin based treatment of type 2 diabetes mellitus.
- **Complex care clinics** - if you are unsure about how to proceed with altering the insulin regimen, consider arranging a complex care clinic with your local DSN. These clinics can be arranged in the GP practice. The DSN will see complex patients with you and put an action plan in place.
  - Wyre Forest 01562 826385
  - Redditch and Bromsgrove 01527 488649
  - South Worcestershire 01905 733834

Guidance for: NHS Redditch and Bromsgrove CCG, NHS South Worcestershire CCG, NHS Wyre Forest CCG - May 2017
593 patients with HbA1c less than 58mmol last year
Prescribed 4080 pens/month = 816 packs
Lantus x5 = £41.50
Abasaglar x5 = £35.28
Based on a switch dose for dose:
816*(41.5-35.28) = £4896
£4896*12=£58,752 savings per year

902 patients with HbA1c greater than 58mmol in last year
Prescribed 7055 pens/month = 1411 packs
Lantus x5 = £41.50
Abasaglar x5 = £35.28
Based on a switch dose for dose:
1411*(41.5-35.28) = £8776.42

£8776.42*12=£105,317 savings per year

Any switches to Toujeo would still result in savings as Toujeo is slightly more cost effective than Lantus on a unit per unit basis. However not as cost effective as Abasaglar.
Lantus unit = 2.77p
Abasaglar unit = 2.35p
Toujeo unit = 2.45p

Total potential savings £164,069
Based only on straight switch from lantus to abasaglar for all patients.

There may be a significant proportion of uncontrolled patients who would be suitable for a switch to twice a day human biphasic insulin eg Insuman Comb 25 or Humulin M3.
If this switch is carried out then savings are far greater per patient.
Lantus x5 = £41.50
Insuman Comb 25 x5 = £19.80 (pfp) (or cheaper £17.50 carts)

If just 30% of the uncontrolled lantus patients switched to Insuman Comb 25 on a pen for pen basis this would save another £110,000.

This saving can’t be guaranteed. However during the process of patient review these changes may occur. Potentially could track these savings with a post switch audit in practice.